<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04143412</url>
  </required_header>
  <id_info>
    <org_study_id>RAAS blockers in albuminuria</org_study_id>
    <nct_id>NCT04143412</nct_id>
  </id_info>
  <brief_title>Efficacy of ACE Inhibitors, MRAs and ACE Inhibitor/ MRA Combination</brief_title>
  <official_title>Antiproteinuric Efficacy of ACE Inhibitors, Selective MRAs and ACE Inhibitor/Selective MRA Combination Therapy in Diabetic Hypertensives With Microalbuminuria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beni-Suef University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beni-Suef University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of our work is to compare the antiproteinuric efficacy of ACEI monotherapy, Selective
      MRA monotherapy and their combination in mildly hypertensive patients with type 2 diabetes
      mellitus and microalbuminuria
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Diabetic nephropathy (DN) is the most common cause renal failure in Western countries,
      responsible for 45% of patients on renal replacement therapy.Diabetic nephropathy was
      characterized in the early stage by increased albumin excretion in urine, known as
      microalbuminuria. (DN) results from interactions between different pathological factors that
      include hyperglycemia, increased activity of the renin-angiotensin-aldosterone-system (RAAS),
      uncontrolled high systemic and glomerular pressure . (DN) optimal therapy continues to
      evolve. The main lines of treatment include strict glycemic and blood pressure (BP) control.
      The angiotensin converting enzyme (ACE) inhibitors have been known to reduce proteinuria both
      in normotensive and hypertensive patients with diabetic nephropathy and in hypertensive
      individuals with end stage renal failure . The mechanism by which ACE inhibitors exert their
      effect on proteinuria reduction is still unknown. The control of high systemic arterial
      pressure can be beneficial by reducing the filtration pressure. However, no association has
      been found between antihypertensive effect and proteinuria reduction in several studies.
      Microalbuminuria which is an early sign of nephropathy can be decreased also by use of
      Angiotensin receptor blockers (ARBs) in patients with type 2 diabetes mellitus . Insufficient
      blockade of aldosterone may lead to inadequate anti-albuminuric effects. Studies show that
      renin-angiotensin-aldosterone system inhibition with ACEI/ARB alone sometimes does not
      achieve optimal renoprotective effects and does not reduce progression of renal disease,
      despite therapy. Addition of mineralocorticoid receptor antagonists (MRAs) to
      angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker therapy was found
      to reduce proteinuria in patients diabetic nephropathy and can delay progression of renal
      dysfunction.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 4, 2019</start_date>
  <completion_date type="Anticipated">March 2020</completion_date>
  <primary_completion_date type="Anticipated">February 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Three parallel groups of therapy; Ramipril 10 mg monotherapy (25 patients) ,Eplerenone 50 mg monotherapy (25 patients) and combination therapy of Eplernone/Ramipril 50/10 mg (25 patients)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Single blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Urinary albumin/creatinin ratio (UACR)</measure>
    <time_frame>24 weeks</time_frame>
    <description>Percentage change in albumin/creatinin ratio compared with the baseline value</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>24 weeks</time_frame>
    <description>change in blood pressure level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>estimated Glomerular Filtration Rate (e GFR)</measure>
    <time_frame>24 weeks</time_frame>
    <description>change in estimated Glomerular Filtration Rate (e GFR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum K</measure>
    <time_frame>24 weeks</time_frame>
    <description>change in serum K level</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Diabetic Nephropathy Type 2</condition>
  <condition>Microalbuminuria Due to Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Tritace (Ramipril)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>25 patients with type 2 diabetes mellitus and mild hypertension will be randomized to Tritace (Ramipril) 10 mg/ day. Full doses will be reached by forced titration after 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Eraloner (Eplerenone)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>25 patients with type 2 diabetes mellitus and mild hypertension will be randomized to Eraloner (Eplerenone) 50 mg/ day. Full doses will be reached by forced titration after 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tritace/Eraloner (Ramipril/Eplerenone)combination therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>25 patients with type 2 diabetes mellitus and mild hypertension will be randomized to Tritace/Eraloner (Ramipril 10 mg / Eplerenone 50 mg ) / day. Full doses will be reached by forced titration after 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tritace (Ramipril 10 mg)</intervention_name>
    <description>Stratified randomized clinical trial</description>
    <arm_group_label>Eraloner (Eplerenone)</arm_group_label>
    <arm_group_label>Tritace (Ramipril)</arm_group_label>
    <arm_group_label>Tritace/Eraloner (Ramipril/Eplerenone)combination therapy</arm_group_label>
    <other_name>Eraloner (Eplerenone 50 mg)</other_name>
    <other_name>Tritace/ Eraloner (Ramipril 10 mg/ Eplerenone 50 mg)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult male and non-pregnant female patients with established diagnosis of type 2 DM at
             least five years ago with glycosylated hemoglobin (HbA1c) ≤ 8.5%

          -  Age 30-80 Y

          -  Stage 1 hypertension (systolic BP 140-159 mmHg and/or diastolic BP 90-99 mmHg) and
             microalbuminuria diagnosed by measuring Urinary albumin/creatinine ratio (UACR) .
             Microalbuminuria was defined at a level between (30-300 mg/g)

          -  Patients included in our study had never been treated with ACEIs, ARBs or aldosterone
             antagonists, serum potassium level ≥ 3.5 and ≤ 5.0 mmol/L before randomization with
             estimated glomerular filtration rate (e GFR) ≥50 mL/min/1.73 m2

        Exclusion Criteria:

          -  Patients with type 1 diabetes mellitus

          -  Patients with BP ≥ 160/100 mmHg

          -  Patients with secondary hypertension

          -  Non-diabetic nephropathy including (chronic glomerulonephritis, polycystic kidney
             disease and nephrosclerosis),

          -  Confirmed bilateral renal artery stenosis or stenosis of the renal artery in solitary
             functioning kidney

          -  History of New York Heart Association functional class III and IV heart failure

          -  Patients with rapid progression of kidney disease and women who were pregnant,
             breast-feeding, or planning to become pregnant during the study period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mostafa O El Mokadem, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cardiology department,Faculty of Medicine, Beni-Suef University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mostafa O El Mokadem, M.D.</last_name>
    <phone>+201009414408</phone>
    <email>mostafa.elmokadem9@med.bsu.edu.eg</email>
  </overall_contact>
  <location>
    <facility>
      <name>Faculty of Medicine,Beni-Suef University</name>
      <address>
        <city>Banī Suwayf</city>
        <zip>62511</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mostafa O El Mokadem, M.D.</last_name>
      <phone>+201009414408</phone>
      <email>mostafa.elmokadem9@med.bsu.edu.eg</email>
    </contact>
    <contact_backup>
      <last_name>Yasser A Abd el Hady, M.D.</last_name>
      <phone>+201001775524</phone>
      <email>Yasser.abdelhady@icloud.com</email>
    </contact_backup>
    <investigator>
      <last_name>Yasser A Abd el hady, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ashref A Wasfy, MBBch</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Espinel E, Agraz I, Ibernon M, Ramos N, Fort J, Serón D. Renal Biopsy in Type 2 Diabetic Patients. J Clin Med. 2015 May 18;4(5):998-1009. doi: 10.3390/jcm4050998. Review.</citation>
    <PMID>26239461</PMID>
  </reference>
  <reference>
    <citation>Zelmanovitz T, Gerchman F, Balthazar AP, Thomazelli FC, Matos JD, Canani LH. Diabetic nephropathy. Diabetol Metab Syndr. 2009 Sep 21;1(1):10. doi: 10.1186/1758-5996-1-10.</citation>
    <PMID>19825147</PMID>
  </reference>
  <reference>
    <citation>Cao Z, Cooper ME. Pathogenesis of diabetic nephropathy. J Diabetes Investig. 2011 Aug 2;2(4):243-7. doi: 10.1111/j.2040-1124.2011.00131.x. Review.</citation>
    <PMID>24843491</PMID>
  </reference>
  <reference>
    <citation>Satirapoj B, Adler SG. Prevalence and Management of Diabetic Nephropathy in Western Countries. Kidney Dis (Basel). 2015 May;1(1):61-70. doi: 10.1159/000382028. Epub 2015 May 1. Review.</citation>
    <PMID>27536666</PMID>
  </reference>
  <reference>
    <citation>Jalal S, Sofi FA, Abass SM, Alai MS, Bhat MA, Rather HA, Lone NA, Siddiqi MA. Effect of amlodipine and lisinopril on microalbuminuria in patients with essential hypertension: A prospective study. Indian J Nephrol. 2010 Jan;20(1):15-20. doi: 10.4103/0971-4065.62090.</citation>
    <PMID>20535265</PMID>
  </reference>
  <reference>
    <citation>Galle J. Reduction of proteinuria with angiotensin receptor blockers. Nat Clin Pract Cardiovasc Med. 2008 Jul;5 Suppl 1:S36-43. doi: 10.1038/ncpcardio0806. Review.</citation>
    <PMID>18580865</PMID>
  </reference>
  <reference>
    <citation>Cagnoni F, Njwe CA, Zaninelli A, Ricci AR, Daffra D, D'Ospina A, Preti P, Destro M. Blocking the RAAS at different levels: an update on the use of the direct renin inhibitors alone and in combination. Vasc Health Risk Manag. 2010 Aug 9;6:549-59. Review.</citation>
    <PMID>20730071</PMID>
  </reference>
  <reference>
    <citation>Cooper LB, Lippmann SJ, Greiner MA, Sharma A, Kelly JP, Fonarow GC, Yancy CW, Heidenreich PA, Hernandez AF. Use of Mineralocorticoid Receptor Antagonists in Patients With Heart Failure and Comorbid Diabetes Mellitus or Chronic Kidney Disease. J Am Heart Assoc. 2017 Dec 23;6(12). pii: e006540. doi: 10.1161/JAHA.117.006540.</citation>
    <PMID>29275368</PMID>
  </reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>October 26, 2019</study_first_submitted>
  <study_first_submitted_qc>October 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 29, 2019</study_first_posted>
  <last_update_submitted>January 14, 2020</last_update_submitted>
  <last_update_submitted_qc>January 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beni-Suef University</investigator_affiliation>
    <investigator_full_name>Mostafa El Mokadem</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>microalbuminuria</keyword>
  <keyword>Diabetic nephropathy</keyword>
  <keyword>Hperkalemia</keyword>
  <keyword>Eplerenone</keyword>
  <keyword>Ramipril</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Diabetic Nephropathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ramipril</mesh_term>
    <mesh_term>Eplerenone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>To respect privacy and confidentiality of our patients</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

